Issue Archive
Table of Contents
Inside blood
Antivascular combo therapy: up-and-coming
The process of angiogenesis contributes to leukemogenesis, indicating a place for angiotargeting therapy in the treatment of AML. In this issue of Blood, Madlambayan and colleagues demonstrate that combining antivascular agents that target endothelial cells and modulate the local cytokine network can be an effective therapeutic strategy in the fight against leukemia.1 The authors combined the VEGF-specific antibody bevacizumab with the vascular disrupting agent OXi4503. This combination may soon become a clinical reality: bevacizumab is already in clinical use and a clinical trial of OXi4503 in treatment of AML was recently registered (ClinicalTrials.gov identifier: NCT01085656).
Balancing act for elderly myeloma
In this issue of Blood, Waage and colleagues present a phase 3 study comparing the combination melphalan-prednisone-thalidomide (MPT) with melphalan-prednisone plus placebo (MP) for the treatment of elderly patients with multiple myeloma. Though responses were in favor of MPT, they did not translate in prolonged progression-free or overall survival.
JAK2 impairs stem cell function?
In this issue of Blood, Li et al report that JAK2-V617F increases DNA damage and impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2-V617F–positive essential thrombocythemia.1
NOX-free inflammasome activation
In this issue of Blood, Meissner and colleagues discover that immune cells from CGD patients that have defective phagocyte oxidases show hyperactive inflammasome activation. These findings implicate that ROS down-regulate rather than enable caspase-1 activation and identify anti–IL-1 strategies as a potential therapy for the disproportionate inflammatory responses associated with CGD.
Sometimes a cigar is just a cigar
In this issue of Blood, Connolly and colleagues describe an elegant approach to studying the significance of specific molecular interactions in vivo. The authors have “knocked-in” a mutant form of the protease, urokinase-type plasminogen activator (uPA), into the murine uPA locus, to create a mouse strain (PlauGFDhu/GFDhu) where the interaction between endogenous uPA and its receptor (uPAR) is selectively disrupted, while leaving other functions of both uPA and uPAR intact. Their findings suggest that the primary role of uPAR in vivo is to promote fibrinolysis within tissues through localization of uPA, and that many of the previously described activities of uPAR may be secondary to this process.1
Blood Work
Review Article
Clinical Trials and Observations
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Clinical Trials & Observations
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group
Clinical Trials & Observations
Hematopoiesis and Stem Cells
Immunobiology
Lymphoid Neoplasia
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
Myeloid Neoplasia
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Clinical Trials & Observations
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation
Phagocytes, Granulocytes, and Myelopoiesis
Red Cells, Iron, and Erythropoiesis
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
Thrombosis and Hemostasis
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation
Vascular Biology
Errata
-
Cover Image
Cover Image
Iron transport into the glomerular filtrate has recently been demonstrated. Confocal microscopy revealed accumulations of ferritin (green) near the apical brush border of a proximal convoluted tubule. Ferritin colocalized with villin (red), an actin-binding protein involved in formation of microvilli in the intestine and the kidney. Iron reabsorbed from the glomerular filtrate may be loaded onto ferritin near the apical brush border, enabling the proximal tubule cells to prevent excretion of iron in urine. As ferritin is also found in a punctate distribution near the basolateral membrane, it is possible that ferritin translocates across basolateral cells to enter the lysosomal compartment, from which iron may be secreted into the renal interstitium and the circulation by a nonclassical pathway. Both macrophages and proximal tubule cells may be the source of secreted ferritin, which traffics through a nonclassical pathway that involves lysosomes. See the article by Cohen et al on page 1574.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals